Supernus Pharmaceuticals, Inc. filed a Form 8-K on October 26, 2026, disclosing the October 20, 2026 termination of its UBS Credit Line Agreement with UBS Bank USA in connection with its pending business combination with Indivior Pharmaceuticals, Inc.

Key Highlights

  • Agreement terminated: The UBS Credit Line Agreement, originally dated February 8, 2023, was terminated on October 20, 2026.
  • No outstanding obligations: As of the termination date, there were no advances, letters of credit, or other borrowings or obligations outstanding under the UBS Credit Line.
  • No penalties incurred: According to the filing, the company did not incur any early termination penalties in connection with the termination.
  • Collateral released: UBS Bank USA's security interests in the collateral securing the credit line were released upon termination.
  • Merger context: The termination was made in anticipation of, and in connection with, the company's previously announced business combination with Indivior Pharmaceuticals, Inc. pursuant to an Agreement and Plan of Merger dated August 1, 2026.
  • New facility planned: The filing notes the termination was made in contemplation of a new senior secured credit facility to be entered into by the combined company at the closing of the merger transaction.

Supernus Closes Out UBS Credit Facility Ahead of Planned Merger Closing

According to the Form 8-K filed with the SEC by Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) on October 26, 2026, the company terminated its UBS Credit Line Agreement with UBS Bank USA on October 20, 2026. The credit line, originally established on February 8, 2023, provided the company with an uncommitted, demand revolving line of credit secured by a pledge of a securities collateral account maintained with UBS Bank USA and related assets.

The filing states that the termination was carried out "in anticipation of, and in connection with, the completion of the Company's previously announced business combination with Indivior Pharmaceuticals, Inc. pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026." The company also cited the contemplated entry into a new senior secured credit facility by the combined entity at the closing of that transaction as a factor in the decision to terminate the existing line.

The company disclosed that at the time of termination, no amounts were drawn and no obligations were outstanding under the facility. The filing further states that no early termination penalties were incurred, and that all security interests held by the bank in the collateral were released as part of the termination process. The 8-K was signed by Timothy C. Dec, Senior Vice President and Chief Financial Officer of Supernus Pharmaceuticals, Inc.

What Was Disclosed

Supernus Pharmaceuticals disclosed the October 20, 2026 termination of its UBS Credit Line Agreement, citing the pending merger with Indivior Pharmaceuticals, Inc. No balances were outstanding at termination, no penalties were incurred, and the bank's collateral security interests were released.